Takeda Pharmaceutical Co ADR (NYSE:TAK) traded with a subtraction of -$0.38 to $15.57 on Thursday, a downside of -2.35 percent. An average of 1,322,083 shares of common stock have been traded in the last five days. There was a fall of -$0.36 in the past week, and it reached a new high 29 times over the past 12 months. The last 20 days have seen an average of 1,625,016 shares traded, while the 50-day average volume stands at 2,115,164.
TAK stock has increased by 1.47% in the last month. The company shares reached their 1-month lowest point of $15.14 on 09/06/23. With the stock rallying to its 52-week high on 04/06/23, shares of the company touched a low of $12.28 and a high of $17.15 in 52 weeks. It has reached a new high 11 times so far this year and lost -0.16% or -$0.03 in price. In spite of this, the price is down -9.18% from the 52-week high.
Valuation Metrics
Takeda Pharmaceutical Co ADR (TAK) has a trailing price-to-earnings (P/E) ratio of 22.53, which compares with the N/A for the broader industry. The stock’s beta is 0.62. Other valuation ratios to consider include the trailing price-to-sales (P/S) ratio at 1.62, the price-to-book (PB) ratio at 1.01, and the price-to-cash flow ratio at 8.78.
Financial Health
The quick ratio of Takeda Pharmaceutical Co ADR for the recent quarter was 0.56, and the current ratio was 0.99, indicating that the company is not able to meet its debt obligations. Further, the company has a long term debt to equity ratio of 0.63 and a total debt to equity ratio of 0.69 for the recent quarter. Takeda Pharmaceutical Co ADR’s EBITDA margin is 32.84%, while its operating margin for the same period stands at 15.34%. Its gross profit as reported stood at $20.6 billion compared to revenue of $29.8 billion.
Earnings Surprise
For the recent quarter, Takeda Pharmaceutical Co ADR had $453.01 million in total debt. In the quarter under review, the net income was up than the previous quarter. The company posted a net income of $2.2 billion in the quarter, while revenues were grew 23.27%.
Technical Picture
From a technical analysis perspective, let’s take a brief look at Takeda Pharmaceutical Co ADR (TAK) price momentum. RSI 9-day as of the close on 27 September was 37.83%, suggesting the stock is Neutral, with historical volatility in this time frame at 15.51%.
As of today, TAK’s price is $15.86 -2.23% or -$0.36 from its 5-day moving average. TAK is currently trading +1.73% higher than its 20-day SMA and -7.68% lower than its 100-day SMA. However, the stock’s current price level is +0.87% above the SMA50 and +3.97% above the SMA200.
The stochastic %K and %D were 48.46% and 58.38%, respectively, and the average true range (ATR) was 0.20. With the 14-day stochastic at 18.50% and the average true range at 0.19, the RSI (14) stands at 44.95%. The stock has reached -0.19 on the 9-day MACD Oscillator while the 14-day reading was at -0.17.
Analyst Ratings
BofA Securities upgraded Takeda Pharmaceutical Co ADR (NYSE: TAK) to a a Buy rating in its most recent analyst report. Previously, the stock was rated as a Neutral. The consensus rating for Takeda Pharmaceutical Co ADR (TAK) among analysts is Overweight. According to current brokerage recommendations, 0 brokerage firms advise that investors sell TAK, while 10 suggest investors hold. There are 0 analysts who rate the stock as underweight. The stock is rated overweight by 1 analysts, while 6 others rate it as a “buy”.
What is TAK’s price target for the next 12 months?
Analysts predict a range of price targets between $12.80 and $20.67, with a median target of $16.43. Taking a look at these predictions, the average price target given by analysts for Takeda Pharmaceutical Co ADR (TAK) stock is $16.52.
